News for BWAY Stock

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD) BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025 BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights BrainsWay to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025 BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024 BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners BrainsWay Announces Significant Expansion on U.S. East Coast Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024 BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024 BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction BrainsWay to Report Third Quarter 2023 Financial Results on November 15, 2023 BrainsWay Announces Presentation of Two Deep TMS™ Posters at Upcoming World Congress of Psychiatry BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie’s Way Plus BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S. BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights BrainsWay Announces Publication of Three New Deep TMS Research Publications BrainsWay to Report Second Quarter 2023 Financial Results on August 9, 2023 BrainsWay Accelerates International Expansion in India BrainsWay Announces Significant Expansion in Western and Central U.S. BrainsWay Announces Appointment of Ido Marom as CFO BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights BrainsWay Launches Investigator Initiated Study (IIS) Program BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023 BrainsWay to Participate in Clinical TMS Society and American Psychiatric Association Meetings BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights BrainsWay Named to Fast Company’s 2023 List of the World’s Most Innovative Companies BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award BrainsWay Announces Appointment of Hadar Levy as CEO BrainsWay Announces Appointment of Ami Boehm as New Chairman Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™ BrainsWay Resolves Neuronetics Litigation BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom BrainsWay Reports Open Market Stock Purchases by Two Board Members BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™ BrainsWay to Report Third Quarter Financial Results on November 16, 2022 BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™ BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights BrainsWay to Report Second Quarter Financial Results on August 10, 2022 BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™ BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society BrainsWay to Report First Quarter Financial Results on May 11, 2022 BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy BrainsWay to Host Key Opinion Leader Webinar on Deep TMS™ Therapy for Treating Anxious Depression BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference BrainsWay to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022 BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects BrainsWay to Present at the Sidoti December Micro-Cap Investor Conference BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021 BrainsWay Announces Prominent Addition to Scientific Advisory Board BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction BrainsWay to Participate in Two Upcoming Investor Conferences BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021 MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) BrainsWay to Present at the Ladenburg Thalmann 2021 Healthcare Conference BrainsWay to Present at the Raymond James Human Health Innovation Conference BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield® Licensee HCSC BrainsWay Announces First Draft Proposal for OCD Coverage by a Regional Medicare Administrative Contractor BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™ BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights BrainsWay to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021 BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS) BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021 BrainsWay to Present at the Oppenheimer 31st Annual Healthcare Conference BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales BrainsWay Reports Preliminary Record Fourth Quarter Revenue and Full-Year 2020 Financial Results BrainsWay Signs Exclusive Distribution Agreement with Gaelan Medical Trade LLC BrainsWay Reports Third Quarter 2020 Financial Results and Operational Highlights BrainsWay Hosting Key Opinion Leader Call on Deep Transcranial Magnetic Stimulation for Treating Psychiatric Disorders BrainsWay Announces Publication of New Real-World OCD Data for its Deep TMS System in Journal of Psychiatric Research BrainsWay to Report Third Quarter 2020 Financial Results and Operational Highlights on November 18, 2020 BrainsWay to Participate in Two Upcoming Investor Conferences BrainsWay Debuts “#TheRealOCD” Campaign and Video on Obsessive-Compulsive Disorder (OCD) BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session BrainsWay to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit BrainsWay Announces Presentations at Upcoming Investor Conferences BrainsWay Receives FDA Clearance for Smoking Addiction in Adults BrainsWay Reports Second Quarter 2020 Financial Results and Operational Highlights BrainsWay to Report Second Quarter 2020 Financial Results and Operational Highlights on August 12, 2020